NCT01218204 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin | Biotech Hunter

Enrollment

287

Participants

Timeline

Start Date

September 14, 2010

Primary Completion Date

June 29, 2011

Study Completion Date

June 29, 2011

Conditions

DyslipidaemiasDyslipidemias

Interventions

DRUG

10mg atorvastatin

10mg

DRUG

80mg atorvastatin

80mg

DRUG

GSK1292263 Placebo

Placebo

DRUG

100mg GSK1292263

100mg

DRUG

300mg GSK1292263

300mg

DRUG

800mg GSK1292263

800mg

DRUG

10mg ezetimibe

10mg

OTHER

Washout

No interventions - washout period

Trial Locations (21)

29303

GSK Investigational Site, Spartanburg

32127

GSK Investigational Site, Port Orange

32216

GSK Investigational Site, Jacksonville

33169

GSK Investigational Site, Miami

33183

GSK Investigational Site, Miami

33709

GSK Investigational Site, St. Petersburg

36207

GSK Investigational Site, Anniston

40213

GSK Investigational Site, Louisville

45246

GSK Investigational Site, Cincinnati

49007

GSK Investigational Site, Kalamazoo

55430

GSK Investigational Site, Minneapolis

60607

GSK Investigational Site, Chicago

60610

GSK Investigational Site, Chicago

73112

GSK Investigational Site, Oklahoma City

78205

GSK Investigational Site, San Antonio

78229

GSK Investigational Site, San Antonio

91910

GSK Investigational Site, Chula Vista

95204

GSK Investigational Site, Stockton

97404

GSK Investigational Site, Eugene

98057

GSK Investigational Site, Renton

08009

GSK Investigational Site, Berlin